Document is current
Any future updates will be listed below
-
Authors
Ma, Yilei
Yu, Peihao
Wang, Xiaofen
Chen, Ruofei
Ni, Wei
Liu, Huixing
Fang, Xinru
Zhao, Feng
Hu, Qianwen
Qiao, Sai
Yang, Suwen
Jin, Hong
Song, Jingjuan
Zhao, Dongdong
Fang, Lei
Zhang, Jun
Zhou, Jiancang
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82471782)
National Natural Science Foundation of China (82472351)
- License Information
-
More Information
Article History
Received: 9 May 2026
Accepted: 25 June 2026
First Online: 27 June 2026
Declarations
:
: This work was approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (No. 2025 − 0406). It was conducted in accordance with the Declaration of Helsinki, GCP, and relevant national and institutional regulations. The Ethics Committee approved the use of de-identified residual EDTA-anticoagulated blood after routine testing from ICU patients and routine health-examination individuals and waived written informed consent. No additional blood was drawn.
: Not applicable.
: Y.L.M. and J.C. Z. are inventors on patent(s) or patent application(s) related to EMR3/ADGRE3 as a biomarker and/or anti-EMR3 antibody related applications. The remaining authors declare no competing interests.
